All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.
President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS
Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System